IL139019A0 - Spla2 inhibitor compounds for treatment of disease - Google Patents
Spla2 inhibitor compounds for treatment of diseaseInfo
- Publication number
- IL139019A0 IL139019A0 IL13901999A IL13901999A IL139019A0 IL 139019 A0 IL139019 A0 IL 139019A0 IL 13901999 A IL13901999 A IL 13901999A IL 13901999 A IL13901999 A IL 13901999A IL 139019 A0 IL139019 A0 IL 139019A0
- Authority
- IL
- Israel
- Prior art keywords
- disease
- treatment
- inhibitor compounds
- spla2 inhibitor
- spla2
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/22—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an aralkyl radical attached to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8387498P | 1998-05-01 | 1998-05-01 | |
| PCT/US1999/008654 WO1999057100A1 (en) | 1998-05-01 | 1999-04-20 | Spla2 inhibitor compounds for treatment of disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL139019A0 true IL139019A0 (en) | 2001-11-25 |
Family
ID=22181224
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL13901999A IL139019A0 (en) | 1998-05-01 | 1999-04-20 | Spla2 inhibitor compounds for treatment of disease |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US6340699B1 (cs) |
| EP (1) | EP1084108A4 (cs) |
| JP (1) | JP2002513783A (cs) |
| KR (1) | KR20010043190A (cs) |
| CN (1) | CN1299348A (cs) |
| AU (1) | AU3656299A (cs) |
| BR (1) | BR9910095A (cs) |
| CA (1) | CA2330856A1 (cs) |
| CZ (1) | CZ20004052A3 (cs) |
| EA (1) | EA200001140A1 (cs) |
| HR (1) | HRP20000739A2 (cs) |
| HU (1) | HUP0102243A2 (cs) |
| ID (1) | ID27153A (cs) |
| IL (1) | IL139019A0 (cs) |
| NO (1) | NO20005479L (cs) |
| PL (1) | PL343708A1 (cs) |
| SK (1) | SK16342000A3 (cs) |
| TR (1) | TR200003194T2 (cs) |
| WO (1) | WO1999057100A1 (cs) |
| ZA (1) | ZA200005563B (cs) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19962300A1 (de) * | 1999-12-23 | 2001-06-28 | Asta Medica Ag | Substituierte N-Benzyl-Indol-3-yl-glyoxylsäure-Derivate mit Antitumorwirkung |
| WO2001055108A2 (en) * | 2000-01-25 | 2001-08-02 | Eli Lilly And Company | Use of spl a2 inhibitors for the treatment of inflammation |
| JPWO2002000621A1 (ja) | 2000-06-29 | 2004-04-22 | 塩野義製薬株式会社 | Ｘ型ｓＰＬＡ２阻害作用を有する化合物 |
| AU2002224531B2 (en) * | 2000-07-24 | 2005-08-25 | Dow Global Technologies Inc. | Thermoplastic superabsorbent polymer blend compositions and their preparation |
| CA2627353A1 (en) * | 2005-11-03 | 2007-05-18 | Ilypsa, Inc. | Indole compounds having c4-acidic substituents and use thereof as phospholipase-a2 inhibitors |
| CN101983188A (zh) * | 2008-04-01 | 2011-03-02 | 安斯泰来制药有限公司 | 吲哚啉酮化合物 |
| NZ720946A (en) | 2009-04-29 | 2017-09-29 | Amarin Pharmaceuticals Ie Ltd | Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same |
| US9290752B2 (en) | 2013-03-13 | 2016-03-22 | Sunny Delight Beverages Co. | Process for enhancing the amylase inhibitory efficacy from phaseolus vulgaris extracts |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5356919A (en) | 1991-05-30 | 1994-10-18 | G. D. Searle & Co. | Leukotriene B4 synthesis inhibitors |
| DE4218096A1 (de) | 1992-06-02 | 1993-12-09 | Boehringer Mannheim Gmbh | Spiro-oxetane, Verfahren zu ihrer Herstellung und Arzneimittel |
| DE4323409A1 (de) | 1993-07-13 | 1995-01-19 | Boehringer Mannheim Gmbh | Verwendung von Cumarinen und Carbostyrilen als PLA¶2¶-Inhibitoren, neue Cumarine und Carbostyrile, Verfahren zu ihrer Herstellung und Arzneimittel |
| JP3109974B2 (ja) * | 1994-04-01 | 2000-11-20 | イーライ・リリー・アンド・カンパニー | １Ｈ−インドール−３−グリオキシルアミドｓＰＬＡ２阻害剤 |
| WO1995033462A1 (en) * | 1994-06-02 | 1995-12-14 | Smithkline Beecham Corporation | Anti-inflammatory compounds |
| NZ298145A (en) | 1994-12-29 | 1998-08-26 | Yamanouchi Pharma Co Ltd | Monoclonal antibodies having inhibitory effect on type ii phospholipase a2, proteins forming part thereof, cells producing them, dna encoding them, recombinant vector comprising the dna and medicament |
| KR20000049210A (ko) | 1996-10-30 | 2000-07-25 | 피터 지. 스트링거 | 치환된 트리시클릭류 |
| PL343007A1 (en) * | 1998-02-25 | 2001-07-30 | Genetics Inst | Inhibitors of phospholipase enzymes |
-
1999
- 1999-04-20 TR TR2000/03194T patent/TR200003194T2/xx unknown
- 1999-04-20 PL PL99343708A patent/PL343708A1/xx unknown
- 1999-04-20 KR KR1020007012113A patent/KR20010043190A/ko not_active Withdrawn
- 1999-04-20 EA EA200001140A patent/EA200001140A1/ru unknown
- 1999-04-20 ID IDW20002214A patent/ID27153A/id unknown
- 1999-04-20 CN CN99805675A patent/CN1299348A/zh active Pending
- 1999-04-20 JP JP2000547070A patent/JP2002513783A/ja not_active Withdrawn
- 1999-04-20 SK SK1634-2000A patent/SK16342000A3/sk unknown
- 1999-04-20 IL IL13901999A patent/IL139019A0/xx unknown
- 1999-04-20 HR HR20000739A patent/HRP20000739A2/hr not_active Application Discontinuation
- 1999-04-20 BR BR9910095-9A patent/BR9910095A/pt not_active Application Discontinuation
- 1999-04-20 WO PCT/US1999/008654 patent/WO1999057100A1/en not_active Ceased
- 1999-04-20 HU HU0102243A patent/HUP0102243A2/hu unknown
- 1999-04-20 EP EP99918711A patent/EP1084108A4/en not_active Withdrawn
- 1999-04-20 AU AU36562/99A patent/AU3656299A/en not_active Abandoned
- 1999-04-20 CA CA002330856A patent/CA2330856A1/en not_active Abandoned
- 1999-04-20 CZ CZ20004052A patent/CZ20004052A3/cs unknown
- 1999-04-20 US US09/673,675 patent/US6340699B1/en not_active Expired - Fee Related
-
2000
- 2000-10-10 ZA ZA200005563A patent/ZA200005563B/en unknown
- 2000-10-31 NO NO20005479A patent/NO20005479L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| US6340699B1 (en) | 2002-01-22 |
| HRP20000739A2 (en) | 2001-10-31 |
| EA200001140A1 (ru) | 2001-04-23 |
| WO1999057100A1 (en) | 1999-11-11 |
| EP1084108A1 (en) | 2001-03-21 |
| KR20010043190A (ko) | 2001-05-25 |
| CN1299348A (zh) | 2001-06-13 |
| CA2330856A1 (en) | 1999-11-11 |
| SK16342000A3 (sk) | 2002-04-04 |
| EP1084108A4 (en) | 2005-01-12 |
| JP2002513783A (ja) | 2002-05-14 |
| ID27153A (id) | 2001-03-08 |
| PL343708A1 (en) | 2001-08-27 |
| NO20005479L (no) | 2000-12-20 |
| BR9910095A (pt) | 2000-12-26 |
| TR200003194T2 (tr) | 2001-03-21 |
| HUP0102243A2 (hu) | 2001-10-28 |
| AU3656299A (en) | 1999-11-23 |
| ZA200005563B (en) | 2002-01-10 |
| NO20005479D0 (no) | 2000-10-31 |
| CZ20004052A3 (cs) | 2002-05-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2001282873A1 (en) | Quinuclidine-substituted aryl compounds for treatment of disease | |
| AU2001284645A1 (en) | Quinuclidine-substituted aryl compounds for treatment of disease | |
| IL160884A0 (en) | Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease | |
| IL139516A0 (en) | Methods for identifying pathways of drug action | |
| GB9824436D0 (en) | Methods of treatment | |
| IL137540A0 (en) | Inhibitors of phospholipase a2 | |
| HRP20020253A2 (en) | Compounds for the treatment of ischemia | |
| PL342469A1 (en) | Method of obtaining stilbenic compounds | |
| IL141273A0 (en) | Improved method for targeted topical treatment of disease | |
| ID27214A (id) | Triazolopiridina untuk pengobatan gangguan trombosis | |
| AU8322401A (en) | Indole compounds useful for the treatment of cancer | |
| IL150187A0 (en) | Novel forms of pravastatin sodium | |
| EP1084108A4 (en) | SPLA 2 INHIBITORS FOR THE TREATMENT OF DISEASES | |
| HUP0101947A3 (en) | Combination for the treatment of tumors | |
| EP1107778A4 (en) | TREATMENT OF DISEASE CONDITIONS | |
| IL126681A0 (en) | Treatment of trauma-related conditions | |
| EP1135141A4 (en) | PHOSPHOLIPASE INHIBITORS FOR TREATING CANCER | |
| ID26083A (id) | Paroksetina 10-kamforsulfonat untuk pengobatan gangguan cns | |
| NO20006383L (no) | Fremgangsmåte for behandling | |
| HK1036275A (en) | Spla 2 inhibitor compounds for treatment of disease | |
| EP1143998A4 (en) | TREATMENT OF HYPERTENSION | |
| HUP0203741A3 (en) | Treatment of osteoporosis | |
| AU2001232734A1 (en) | Compositions containing potential spla2 inhibitors for the treatment of pain | |
| AUPP751198A0 (en) | Purification of A1-proteinase inhibitor | |
| GB9918058D0 (en) | Compound for treatment of gi disorders |